CIBA PHARMS CUTTING 350-450 JOBS WITH SALES FORCE TAKING MAIN BLOW
Executive Summary
CIBA PHARMS CUTTING 350-450 JOBS WITH SALES FORCE TAKING MAIN BLOW in the company's latest downsizing. Ciba Pharmaceuticals announced the restructuring April 14. The company will cut the size of the Ciba U.S. division's work force of approximately 4,600 by 7.6% to 9.8% to between roughly 4,250 and 4,150. The company said employees would be informed of their job losses "no later than mid-July" and that decisions as to who to cut would be made by a "special steering committee" that is being formed. The committee will also look at job transition options.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth